1-(2,4-二羟基-3-丙-2-烯基苯基)丙烷-1-酮 | 74815-88-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(2,4-二羟基-3-丙-2-烯基苯基)丙烷-1-酮
• 英文名称: 2,4-dihydroxy-3-allylpropiophenone
• 英文别名: 1-(3-allyl-2,4-dihydroxy-phenyl)-propan-1-one；1-(3-Allyl-2,4-dihydroxy-phenyl)-propan-1-on；1-[2,4-Dihydroxy-3-(prop-2-EN-1-YL)phenyl]propan-1-one；1-(2,4-dihydroxy-3-prop-2-enylphenyl)propan-1-one
• CAS: 74815-88-6
• 化学式: C₁₂H₁₄O₃
• 分子量: 206.241
• InChiKey: JTSVEBCCFNWPQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2,4-二羟基-3-丙-2-烯基苯基)丙烷-1-酮 在 palladium on activated charcoal 氢气 作用下， 以 various solvent(s) 为溶剂， 以100%的产率得到2,4-二羟基-3-丙基苯基乙基酮
  参考文献：
  名称：

  Phenylacetic acid derivatives as hPPAR agonists

  摘要：

  Beginning with the weakly active lead structure 1, a new series of WAR agonists was developed. In vivo glucose and triglyceride lowering activity was obtained by homologation and oxamination to 3, then conversion to substituted benzisoxazoles 4 and 5. Further manipulation afforded benzofurans 6 and 7. Compound 7 was of comparable potency as a glucose and triglyceride lowering agent in insulin resistant rodents to BRL 49653. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00115-x
• 作为产物：
  描述：

  4-(allyloxy)-2-hydroxypropiophenone 反应 1.5h， 以90%的产率得到1-(2,4-二羟基-3-丙-2-烯基苯基)丙烷-1-酮
  参考文献：
  名称：

  Leukotriene receptor antagonists. 1. Synthesis and structure-activity relationships of alkoxyacetophenone derivatives

  摘要：

  A series of derivatives of 2,4-dihydroxy-3-propylacetophenone(1) were prepared and examined for their ability to block leukotriene D4 (LTD4) induced contraction of guinea pig ileum. Straight-chain carboxylic acids where the carboxyl group was separated from the acetophenone moiety by varying numbers of methylenes were evaluated, and maximum activity was obtained with the pentamethylene acid (6). Examination of ring substitution showed that the 2-propyl-3-hydroxy-4-acetyl substitution pattern was required for maximum LTD4 antagonist activity. Additional chain terminal groups were examined, and the acidic 5-tetrazolyl group separated from the acetophenone moiety by four to seven methylenes (26, 23, 27, 28) gave excellent in vitro and in vivo activities. Compound 26 (LY171883) had the best balance of in vitro and in vivo activity. It lacked bronchospastic activity at the doses administered and has been chosen for clinical evaluation.

  DOI：

  10.1021/jm00387a018

文献信息

• 60. Studies in chelation. Part III. The stabilisation of kekulé forms in o-hydroxy-carbonyl compounds
  作者：Wilson Baker、O. M. Lothian

  DOI：10.1039/jr9360000274

  日期：——
• BHAT, V. S.;JOSHI, V. S., INDIAN J. CHEM. B, 28,(1989) N, C. 512-513
  作者：BHAT, V. S.、JOSHI, V. S.

  DOI：——

  日期：——
• MARSHALL W. S.; GOODSON T.; CULLINAN G. J.; SWANSON-BEAN D.; HAISCH K. D.+, J. MED. CHEM., 30,(1987) N 4, 682-689
  作者：MARSHALL W. S.、 GOODSON T.、 CULLINAN G. J.、 SWANSON-BEAN D.、 HAISCH K. D.+

  DOI：——

  日期：——
• EP0888278A4
  申请人：——

  公开号：EP0888278A4

  公开（公告）日：1999-06-30
• ANTIDIABETIC AGENTS
  申请人：MERCK & CO., INC.

  公开号：EP0888278A1

  公开（公告）日：1999-01-07